Cookies help us deliver our services. By using our services, you agree to our use of cookies.
Learn more
OK
Skip to main content (Press Enter).
Sign In
Skip auxiliary navigation (Press Enter).
Contact Us
Skip main navigation (Press Enter).
Toggle navigation
Search Options
About
What is the AMS
AMS International Scientific Committee
AMS North America Scientific Committee
AMS Educational Executive Committee
AMS Ambassadors
Certifications and Educational Credits
Upcoming Events
Videos & Webinars
International Events
Become a Speaker
Videos On Demand
Education 365
Preview AMS TV
Features
AMS Features
News & Publications
AMS Bookstore
Blogs
Industry
Industry Partners
Become a Sponsor
Features
Blogs
Blog Viewer
Blogs
Cutaneous adverse events of immune checkpoint inhibitor therapy: incidence and types of reactive dermatoses
By
- AMS
posted
Mar 23, 2021 09:21 AM
0
Recommend
.
0 comments
0 views
Permalink
Related Content
COVID-19 in 3 patients treated with immune checkpoint inhibitors for advanced melanoma
- AMS
Added Oct 23, 2020
Blog Entry
A time series analysis of immune checkpoint inhibitor use in the United States Medicare population: 2014–2019
- AMS
Added Aug 11, 2021
Blog Entry
Adverse cutaneous effects of psychotropic medications
- AMS
Added Jan 10, 2014
Blog Entry
Development of immunity-related adverse events correlates with baseline clinical factors, survival and response to anti-PD-1 treatment in patients with inoperable or metastatic melanoma
- AMS
Added Jun 14, 2021
Blog Entry
Data mining for detecting signals of adverse drug reaction of doxycycline using the Korea adverse event reporting system database
- AMS
Added Jun 16, 2021
Blog Entry
© 2022 AMS, Aesthetic Multispecialty Society. All Rights Reserved.
Powered by Higher Logic